RRC ID 77743
Author Kawai K, Sasaki T, Saijo-Kurita K, Akaza H, Koiso K, Ohno T.
Title Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay.
Journal Cancer Immunol Immunother
Abstract The effect of pretreatment with antitumor drugs on lymphokine-activated killer (LAK) cell cytotoxic activity, determined by lactate-dehydrogenase(LDH)-release assay, was investigated. LAK cells were induced by incubating peripheral blood lymphocytes of healthy donors in medium containing interleukin-2 (IL-2) and monoclonal anti-CD3 antibody for 6-7 days. A human lung squamous carcinoma cell line, SQ-5, was used as an adherent target. After 24 h exposure of the target cells to cisplatin, doxorubicin, or mitomycin C, the drugs were washed off and LAK cells were added at an E/T ratio of 5. During further incubation for 48 h, LDH release from cisplatin- or doxorubicin-pretreated target cells was markedly higher than that from non-pretreated target cells. The combination of cisplatin and LAK cells has an additive cytotoxic effect and that of mitomycin C and LAK cells does not; there may also be an additive effect late in the toxicity mechanism between doxorubicin and LAK cells.
Volume 35(4)
Pages 225-9
Published 1992-1-1
DOI 10.1007/BF01789327
PMID 1511457
MeSH Antineoplastic Agents / pharmacology* Carcinoma, Squamous Cell / enzymology Carcinoma, Squamous Cell / pathology Carcinoma, Squamous Cell / therapy Cell Death / drug effects Cell Survival / drug effects Clinical Enzyme Tests / methods Combined Modality Therapy Cytotoxicity, Immunologic Drug Synergism Humans Immunotherapy, Adoptive* Killer Cells, Lymphokine-Activated / drug effects Killer Cells, Lymphokine-Activated / immunology* L-Lactate Dehydrogenase / analysis L-Lactate Dehydrogenase / metabolism* Lung Neoplasms / enzymology Lung Neoplasms / pathology Lung Neoplasms / therapy Time Factors Tumor Cells, Cultured / enzymology
IF 5.442
Human and Animal Cells SQ-5(RCB0110)